ES2640285T3 - Análogos de amilina humana - Google Patents

Análogos de amilina humana Download PDF

Info

Publication number
ES2640285T3
ES2640285T3 ES13723681.6T ES13723681T ES2640285T3 ES 2640285 T3 ES2640285 T3 ES 2640285T3 ES 13723681 T ES13723681 T ES 13723681T ES 2640285 T3 ES2640285 T3 ES 2640285T3
Authority
ES
Spain
Prior art keywords
diacid
amylin
binding
glu
func
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13723681.6T
Other languages
English (en)
Spanish (es)
Inventor
Kirsten Dahl
Lauge SCHÄFFER
Thomas Kruse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Application granted granted Critical
Publication of ES2640285T3 publication Critical patent/ES2640285T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
ES13723681.6T 2012-04-19 2013-04-19 Análogos de amilina humana Active ES2640285T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12164692 2012-04-19
EP12164692 2012-04-19
US201261637806P 2012-04-24 2012-04-24
US201261637806P 2012-04-24
PCT/EP2013/058165 WO2013156594A1 (en) 2012-04-19 2013-04-19 Human amylin analogues

Publications (1)

Publication Number Publication Date
ES2640285T3 true ES2640285T3 (es) 2017-11-02

Family

ID=49382960

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13723681.6T Active ES2640285T3 (es) 2012-04-19 2013-04-19 Análogos de amilina humana

Country Status (7)

Country Link
US (2) US8575091B1 (OSRAM)
EP (2) EP2838914B1 (OSRAM)
JP (1) JP6227629B2 (OSRAM)
CN (1) CN104395338B (OSRAM)
ES (1) ES2640285T3 (OSRAM)
PL (1) PL2838914T3 (OSRAM)
WO (1) WO2013156594A1 (OSRAM)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR097701A1 (es) * 2013-09-19 2016-04-13 Zealand Pharma As Análogos de amilina
EA035791B1 (ru) * 2015-03-18 2020-08-11 Зилэнд Фарма А/С Аналоги амилина
CN106928086B (zh) 2015-12-31 2019-05-31 深圳翰宇药业股份有限公司 一种长链化合物的制备方法
AR109514A1 (es) 2016-09-09 2018-12-19 Zealand Pharma As Análogos de amilina
US11028137B2 (en) 2017-02-01 2021-06-08 The Research Foundation For The State University Of New York Mutant islet amyloid polypeptides with improved solubility and methods for using the same
JP2020510028A (ja) 2017-03-08 2020-04-02 インターシア セラピューティクス，インコーポレイティド 薬物送達デバイスから吐き気誘発性化合物の投与のための装置及び方法
HUE066356T2 (hu) 2017-08-24 2024-07-28 Novo Nordisk As GLP-1 készítmények és alkalmazásaik
KR102911883B1 (ko) 2018-10-11 2026-01-13 인타르시아 세라퓨틱스 인코포레이티드 인간 아밀린 유사체 폴리펩타이드 및 사용 방법
US11666634B2 (en) * 2019-04-24 2023-06-06 The Board Of Regents Of The University Of Texas System Methods and compositions for management of gastrointestinal disorders
CN110467666A (zh) * 2019-09-17 2019-11-19 湖北强耀生物科技有限公司 一种新型胰岛淀粉样多肽的合成方法
PE20221575A1 (es) 2020-02-18 2022-10-06 Novo Nordisk As Formulaciones farmaceuticas
MX2022014309A (es) * 2020-05-15 2022-12-07 Lilly Co Eli Compuestos de insulina acilada de accion temporal prolongada.
JP7674630B2 (ja) * 2020-12-08 2025-05-12 通化安睿特生物製薬股▲フェン▼有限公司 組換えタンパク質を精製する方法
WO2022159395A1 (en) 2021-01-20 2022-07-28 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
TW202400632A (zh) 2021-03-03 2024-01-01 美商美國禮來大藥廠 長效澱粉素受體促效劑及其用途
EP4144362A1 (en) 2021-09-06 2023-03-08 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition
WO2022248419A2 (en) 2021-05-22 2022-12-01 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition
EP4129324A1 (en) 2021-08-02 2023-02-08 Adocia Compositions comprising at least an amylin receptor agonist and a glp-1 receptor agonist
IL311411A (en) 2021-09-15 2024-05-01 Viking Therapeutics Inc Preparations and methods for the treatment of metabolic and liver disorders
CN116621944A (zh) * 2022-02-10 2023-08-22 成都奥达生物科技有限公司 一种长效肝炎病毒进入抑制剂
MX2024005969A (es) 2022-05-30 2024-06-11 Zealand Pharma As Formulaciones liquidas de analogos de amilina.
US12116388B2 (en) 2022-12-22 2024-10-15 Novo Nordisk A/S Amylin receptor agonists
TW202500183A (zh) 2023-06-15 2025-01-01 丹麥商諾佛 儂迪克股份有限公司 包括環糊精的醫藥調配物
TW202545982A (zh) * 2024-02-07 2025-12-01 大陸商江蘇恆瑞醫藥股份有限公司 胰島澱粉樣多肽類似物及其醫藥用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07509008A (ja) 1993-05-12 1995-10-05 ユニバーシティ・オブ・シンシナティ アミリン・アンタゴニストおよびアゴニスト
US5739106A (en) * 1995-06-07 1998-04-14 Rink; Timothy J. Appetite regulating compositions
US7910548B2 (en) 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
EP1053001B1 (en) * 1998-02-13 2010-12-15 Amylin Pharmaceuticals, Inc. Novel mixed amylin activity compounds
DE602005021858D1 (de) 2004-02-11 2010-07-29 Amylin Pharmaceuticals Inc Peptide der amylin familie, verfahren zu deren herstellung und verwendung
AU2005295043A1 (en) * 2004-10-08 2006-04-20 Amylin Pharmaceuticals, Inc. Amylin family polypeptide-6 (AFP-6) analogs and methods of making and using them
JP5252435B2 (ja) * 2006-03-15 2013-07-31 ノボ・ノルデイスク・エー／エス アミリン誘導体
EP2036923A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Improved derivates of amylin
WO2010046357A1 (en) 2008-10-21 2010-04-29 Novo Nordisk A/S Amylin derivatives
CN102292346B (zh) * 2009-01-22 2015-12-02 关键生物科学有限公司 肥胖的治疗
US8748375B2 (en) 2009-03-17 2014-06-10 Amylin Pharmaceuticals, Llc Methods for affecting body composition using amylin agonists
KR102066987B1 (ko) * 2011-06-10 2020-01-16 노보 노르디스크 에이/에스 폴리펩티드

Also Published As

Publication number Publication date
CN104395338B (zh) 2019-05-10
JP6227629B2 (ja) 2017-11-08
PL2838914T3 (pl) 2017-11-30
EP3109256A1 (en) 2016-12-28
US20130281363A1 (en) 2013-10-24
US20140087995A1 (en) 2014-03-27
US8575091B1 (en) 2013-11-05
CN104395338A (zh) 2015-03-04
JP2015514737A (ja) 2015-05-21
EP2838914A1 (en) 2015-02-25
WO2013156594A1 (en) 2013-10-24
EP2838914B1 (en) 2017-06-14
US9023789B2 (en) 2015-05-05

Similar Documents

Publication Publication Date Title
PE20140159A1 (es) Coagonistas del receptor de glucagon/glp-1
ES2558842T3 (es) Agonistas mixtos a base de GIP para el tratamiento de trastornos metabólicos y obesidad
JP4585037B2 (ja) アシル化ｇｌｐ−１化合物
JP4148994B2 (ja) グルカゴン様ペプチド―２アナログ
JP6701075B2 (ja) アミリン類似体
PE20091393A1 (es) Antagonistas de glucagon
PE20231639A1 (es) Compuestos co-agonistas del glucagon y peptido-1 similar al glugacon (glp-1)
WO2007120899A3 (en) Pharmaceutical compositions of hglp-1, exendin-4 and analogs thereof
EP3129041A1 (en) Double-acylated glp-1 compounds
JP2016526012A5 (OSRAM)
US20110275559A1 (en) Long-Acting Y2 and/or Y4 Receptor Agonists
JP2010515686A5 (OSRAM)
JP2013518115A5 (OSRAM)
BR112015032875A2 (pt) derivados de peptídeos do tipo glp-1, e usos dos mesmos
EP2908845A1 (en) Fatty acid acylated amino acids for growth hormone delivery
JP2010515686A (ja) 生理学的ｐＨの緩衝液中で向上した溶解度を示すグルカゴン類縁体
WO2009058734A4 (en) Compounds exhibiting glucagon antagonist and glp-1 agonist activity
JP2013543497A5 (OSRAM)
CA2988500A1 (en) Selective pyy compounds and uses thereof
EP0763061A1 (de) Verfahren zur herstellung von cardiodilatin-fragmenten, hochgereinigte cardiodilatin-fragmente und zwischenprodukte zu deren herstellung
RU2011134596A (ru) Аналоги оксинтомодулина
CN104395338A (zh) 人胰岛淀粉样多肽类似物
ATE541582T1 (de) Stabilisierte pharmazeutische glp-1 peptid zusammensetzungen
RU2018107727A (ru) Новые производные инсулина и их медицинские применения
RU2012153768A (ru) Аналоги паратиреоидного гормона и их применение